ASCO 2026: A Focus on Advancements and Innovations in Oncology

TL;DR

• ASCO 2026 has evolved into a critical strategic event for biopharma executives, investors, BD teams, and clinical leaders seeking signals about where oncology innovation and competitive dynamics are heading.
• Interpreting oncology data now requires more than scientific expertise; meaningful assessment increasingly depends on understanding regulatory precedent, competitive positioning, biomarker strategy, and historical development benchmarks.
• Intelligencia AI identified eight oncology programs expected to generate important ASCO 2026 updates using a framework that combines AI-enabled PTRS modeling with clinical, regulatory, and competitive intelligence.
• The selected programs span targeted therapies, ADCs, cell therapies, transcription-targeting approaches, and novel pathway inhibitors across multiple stages of development.
• While these programs are not predictions of success, they represent potentially important inflection points that could influence future standards of care, development strategies, and market dynamics.
• The central question is not simply whether a study is positive, but whether the magnitude, durability, safety profile, and strategic positioning of the data are sufficient to meaningfully alter competitive landscapes.

AI-Enabled PTRS Assessment Combined with Scientific and Commercial Expertise

ASCO has evolved far beyond a scientific conference. For biopharma executives, investors, business development teams, and clinical strategists, it has become one of the industry’s most important real-time indicators of where oncology innovation — and competitive positioning — is heading next.

Yet interpreting ASCO data in isolation is increasingly insufficient. Clinical outcomes now exist within a highly complex ecosystem shaped by biomarker strategy, evolving standards of care, modality competition, regulatory precedent, and rapidly shifting therapeutic expectations. Understanding whether emerging results meaningfully exceed, match, or fall below historical precedent increasingly requires not only scientific expertise, but also access to large-scale development, regulatory, and competitive benchmarking data. In many cases, the key question is no longer simply whether a study is “positive,” but whether the magnitude, durability, safety profile, and strategic positioning of the data are sufficient to meaningfully alter development trajectories, market dynamics, or future standards of care.

To support that broader strategic understanding, Intelligencia AI identified eight oncology programs expected to generate important data updates around ASCO 2026 that we believe warrant close attention. These programs were selected through Intelligencia AI’s integrated oncology intelligence framework, combining proprietary PTRS modeling, historical development benchmarking, clinical and regulatory datasets, competitive landscape analysis, and expert scientific evaluation to identify programs with potentially meaningful scientific, strategic, or commercial implications heading into ASCO 2026.Importantly, these selections are not intended as predictions of success or investment recommendations. 

For each program, we assess:

• the underlying biological rationale,
• prior clinical performance,
• competitive benchmarks,
• the efficacy and safety thresholds likely required for technical and commercial success,
• and the broader implications a successful outcome could have across the oncology market.

The goal is not simply to identify promising assets, but to provide the context necessary to understand why particular ASCO readouts may matter, what standards they are being measured against, and how they could reshape their competitive landscapes if successful.

Programs Covered in This Analysis

Phase 1 Programs

• PF-07799544 — Brain-Penetrant MEK Inhibitor | BRAF-Mutant Melanoma

Phase 1/2 and Phase 2 Programs

• CRB-701 — Nectin-4 ADC | Head & Neck Cancer
• Zepzelca (Lurbinectedin) — Transcription Inhibitor | Ewing Sarcoma
• OBX-115 — Regulated IL-15 TIL Cell Therapy | Melanoma

Phase 3 Programs

Atebimetinib — Deep Cyclic MAPK Inhibitor | Pancreatic Cancer

Zelenectide Pevedotin — Bicycle Drug Conjugate (BDC) Targeting Nectin-4 | Urothelial Carcinoma

Zegfrovy (Sunvozertinib) — EGFR Exon20ins TKI | NSCLC

Erleada (Apalutamide) — Androgen Receptor Inhibitor | Localized Prostate Cancer

---

Phase 1 Programs

Early-stage oncology development increasingly serves as the industry’s first real test of whether mechanistic rationale can translate into clinically actionable biology. While Phase 1 studies remain primarily focused on safety, dose optimization, and proof-of-concept activity, they also provide some of the earliest signals regarding pathway validity, biomarker strategy, and future competitive positioning.

The programs in this section focus on next-generation targeted therapy approaches designed to address limitations of existing standards, particularly around CNS activity, durability, tolerability, and pathway optimization. In these settings, the central question is not simply whether biological activity can be demonstrated, but whether these programs show enough mechanistic and clinical differentiation to justify broader registrational development in increasingly competitive precision oncology landscapes.

PF-07799544 is one of the more technically interesting early-stage melanoma programs expected to generate attention around ASCO 2026 because it represents Pfizer’s attempt to develop a next-generation, brain-penetrant MEK inhibitor optimized for combination use in BRAF-mutant solid tumors. The drug is being evaluated both as monotherapy and in combination with Pfizer’s next-generation BRAF inhibitor PF-07799933 in advanced melanoma and other solid tumors. Unlike earlier MEK inhibitors, PF-07799544 was specifically engineered for CNS penetration and improved pathway suppression, reflecting growing industry recognition that intracranial disease control and long-term tolerability remain important limitations of current BRAF/MEK regimens.

Why the program matters

BRAF/MEK inhibition is already a well-established therapeutic strategy in melanoma, with approved combinations such as dabrafenib plus trametinib and encorafenib plus binimetinib routinely achieving objective response rates in the ~60–70% range and median progression-free survival approaching ~12–15 months. However, important limitations remain, particularly around CNS progression, acquired resistance, and chronic MEK-associated toxicities that can compromise long-term treatment. Pfizer’s strategy with PF-07799544 appears specifically focused on addressing these limitations through improved CNS penetration, enhanced tolerability, and potential activity in resistant disease settings. 

What the program has shown so far

No formal efficacy outcomes from NCT05538130 appear to have been publicly disclosed thus far. Publicly available information has primarily centered around the study’s dose-escalation design, combination strategy with PF-07799933, and expansion into BRAF V600-mutant melanoma and other solid tumors. The study currently includes both mrapy and combination escalation cohorts intended to define safety, tolerability, and early efficacy signals.

What ASCO 2026 needs to show

The ongoing Phase 1 study is primarily designed around:

• Primary endpoints: Safety, tolerability, dose optimization 
• Key secondary endpoints: ORR, duration of response, pharmacokinetics, CNS activity 

To be viewed as technically successful, initial ASCO data will likely need to demonstrate:

• ORRs approaching ≥50–60%, entering the lower range historically achieved by approved BRAF/MEK combinations such as dabrafenib/trametinib (COMBI-d/COMBI-v) and encorafenib/binimetinib (COLUMBUS) 
• Evidence of intracranial activity 
• Durable responses beyond ~8–10 months 
• A manageable toxicity profile:
  • Particularly lower MEK-associated ocular, GI, and dermatologic toxicity 
• Signals of activity in resistant or previously treated patients 

To be viewed as commercially successful, the bar is substantially higher:

• ORRs and PFS approaching current frontline standards:
  • ~65–70% ORR 
  • ~12–15 month PFS territory 
• Meaningful CNS differentiation versus existing BRAF/MEK combinations 
• Improved tolerability supporting longer treatment duration 
• Evidence of utility after prior BRAF/MEK therapy 
• Potential positioning in brain metastases or resistant disease niches 

If successful, PF-07799544 could strengthen Pfizer’s position in the increasingly competitive BRAF-mutant melanoma landscape and create direct pressure on established regimens from Novartis and Pfizer/Pierre Fabre themselves. More importantly, strong CNS efficacy or improved tolerability could shift competitive focus toward next-generation MAPK-pathway optimization rather than simple pathway blockade alone. In a melanoma market where efficacy among approved BRAF/MEK regimens has largely converged, differentiation through CNS control, durability, and long-term tolerability may increasingly determine competitive relevance.

---

Phase 1/2 and Phase 2 Programs

Mid-stage oncology development is often where promising scientific concepts begin confronting the realities of clinical differentiation, operational scalability, and commercial competitiveness. By this stage, programs are generally expected not only to demonstrate meaningful efficacy signals, but also to establish advantages relative to increasingly sophisticated standards of care and rapidly evolving modality landscapes.

The programs included here span ADC engineering, regulated cell therapy, transcription-targeting approaches, and synthetic lethality strategies in genomically unstable tumors. Several already have preliminary efficacy datasets available, while others are approaching critical expansion-stage inflection points that may determine whether early mechanistic promise can translate into durable clinical and commercial positioning within increasingly competitive oncology markets.

CRB-701 is emerging as one of the more closely followed next-generation ADC programs in head and neck cancer because it targets an increasingly validated solid tumor target — Nectin-4 — while attempting to improve on the limitations of earlier MMAE-based ADCs. The drug was specifically engineered with a site-specific cleavable linker and a controlled site-specific conjugation design, with the goal of maintaining efficacy while reducing the chronic toxicities often associated with first-generation ADCs such as enfortumab vedotin. In recurrent/metastatic HNSCC, where patients progressing after platinum chemotherapy and PD-1 therapy have limited effective options and poor survival outcomes, a differentiated Nectin-4 therapy could fill a meaningful unmet need.

Why the program matters

Post–PD-1 recurrent/metastatic HNSCC remains a major unmet need setting where current second-line therapies typically achieve ORRs of only ~10–20% and median overall survival of ~6–8 months. Nectin-4 is increasingly emerging as a relevant solid tumor target, and CRB-701 aims to improve the therapeutic index of MMAE-based ADCs through optimized linker technology and payload delivery design. The broader strategic question is whether next-generation ADC engineering can preserve efficacy while reducing the chronic neuropathy, rash, and discontinuation burden that has historically limited first-generation MMAE-based therapies. 

What the program has shown so far

Updated Phase 1/2 datasets have generated meaningful early interest, particularly in heavily pretreated HNSCC populations following platinum chemotherapy and PD-1 exposure. At the 3.6 mg/kg dose, CRB-701 demonstrated ORRs approaching ~48%, with disease control rates ranging from ~62–86% across cohorts. Importantly, responses were observed in patients with otherwise limited post-immunotherapy treatment options. Safety has also remained relatively favorable thus far, with adverse events primarily consisting of Grade 1–2 toxicities and limited severe neuropathy or rash signals, while no dose-limiting toxicities were observed during escalation cohorts.

What ASCO 2026 needs to show

The ongoing Phase 1/2 study is expected to provide updated durability and subgroup analyses at ASCO 2026. Future registrational development is expected to focus on:

• Primary endpoint: Objective response rate (ORR) 

Corbus has increasingly framed ongoing expansion development as potentially supportive of accelerated regulatory pathways should response durability and tolerability continue to differentiate from existing post–PD-1 treatment options.

To be viewed as technically successful, updated data will likely need to demonstrate:

• Confirmed ORRs consistently ≥40–45%, substantially exceeding historical physician’s-choice chemotherapy outcomes in post–PD-1 HNSCC and approaching efficacy levels increasingly associated with clinically competitive ADC programs 
• Median duration of response ≥6 months 
• Durable activity across broader patient subsets 
• Continued manageable safety profile 

To be viewed as commercially successful, the program will likely need to demonstrate:

• ORRs consistently ≥50–55% 
  • (Clearly separating from current salvage regimens and prior TK216 experience) 
• Duration of response approaching or exceeding ~9–12 months 
• Clear differentiation versus chemotherapy and competing ADCs 
• Materially lower neuropathy, rash, and discontinuation rates than historical MMAE ADC benchmarks 
• Potential utility in earlier treatment lines or checkpoint inhibitor combinations

If successful, CRB-701 could emerge as a meaningful challenger in the evolving post–PD-1 HNSCC landscape and further validate Nectin-4 as a viable target outside urothelial cancer. More broadly, strong efficacy combined with improved tolerability would place direct competitive pressure on established and emerging ADC programs, particularly enfortumab vedotin (Padcev) and the growing wave of Trop-2 and HER3-directed ADCs from companies such as Daiichi Sankyo, Merck, and Kelun-Biotech. A differentiated safety profile would be especially important, as many current MMAE-based ADCs continue to face limitations related to neuropathy, rash, and treatment discontinuation. If CRB-701 can demonstrate that optimized linker technology and controlled payload delivery materially improve the therapeutic index without sacrificing efficacy, it could help shift industry focus toward next-generation ADC engineering strategies rather than simply pursuing new tumor targets.

Zepzelca (lurbinectedin) is one of the more interesting sarcoma programs expected around ASCO 2026 because it brings an already commercially validated oncology drug into a setting with very limited effective therapies. Lurbinectedin, currently approved in small cell lung cancer, inhibits oncogenic transcription and induces DNA damage — mechanisms considered particularly relevant in transcriptionally driven tumors such as Ewing sarcoma, where the EWS-FLI1 fusion protein is central to disease biology. The ongoing Phase 1/2 NCT05734066 study is evaluating lurbinectedin monotherapy in pediatric and young adult patients with relapsed/refractory disease following encouraging earlier academic and basket-study signals. 

Why the program matters

oRelapsed/refractory Ewing sarcoma remains a severe unmet need where median survival following relapse is often less than 12 months and durable salvage responses remain uncommon. Existing treatment benchmarks remain relatively modest: irinotecan/temozolomide combinations typically produce ORRs in the ~20–30% range, while prior TK216-based approaches demonstrated ORRs ranging from approximately ~14–30%, often with limited durability of only ~3–5 months. Lurbinectedin is particularly interesting in this setting because Ewing sarcoma remains highly dependent on transcriptional dysregulation driven by the EWS-FLI1 fusion protein, providing a biologically plausible rationale for transcription-targeting strategies. Unlike many experimental sarcoma therapies, lurbinectedin also benefits from an already established commercial infrastructure, known systemic safety profile, and prior regulatory familiarity through its approval in small cell lung cancer.  

What ASCO 2026 needs to show

The ongoing study is designed to evaluate:

• Primary objectives: Safety, RP2D selection, and preliminary efficacy 
• Phase 2 focus: Objective response rate (ORR) and durability 

To be viewed as technically successful, initial ASCO data will likely need to demonstrate:

• Confirmed ORRs ≥25–30%, exceeding historical salvage chemotherapy benchmarks established by irinotecan/temozolomide regimens and prior TK216 experience in relapsed Ewing sarcoma 
• Median duration of response ≥4–6 months
  • (Improving upon the ~3–5 month durability often seen with irinotecan-based regimens) 
• Evidence of meaningful disease control in heavily pretreated patients 
• A manageable hematologic safety profile in pediatric/young adult populations 

To be viewed as commercially successful, the bar is substantially higher:

• ORRs approaching or exceeding ~35–40%
  • (Clearly separating from current salvage regimens and prior TK216 experience) 
• Durable responses extending beyond ~6 months 
• Signals of survival improvement versus historical late-line outcomes 
• Potential utility in earlier treatment sequencing or rational combinations 
• Favorable tolerability relative to multi-agent chemotherapy regimens 

If successful, lurbinectedin could become one of the more clinically relevant late-line options in relapsed Ewing sarcoma and strengthen Jazz’s broader oncology franchise beyond SCLC. Competitive implications would likely extend across the emerging sarcoma landscape, particularly for developers pursuing transcriptional and DNA-damage targeting approaches, including PARP inhibitor combinations, TK216-like strategies, and next-generation EWS-FLI1-directed programs. A strong outcome here would also reinforce the growing industry strategy of redeploying approved oncology drugs into molecularly vulnerable rare tumors where development pathways are faster, competition is lighter, and meaningful clinical differentiation can still be achieved.

OBX-115 is one of the more differentiated cell therapy programs expected to generate attention around ASCO 2026 because it attempts to address one of the central limitations of tumor-infiltrating lymphocyte (TIL) therapy: the inability to precisely control immune activation after infusion. The program combines autologous TIL therapy with Obsidian’s cytoDRiVE® regulated expression platform, enabling conditional expression of membrane-bound IL-15 (mbIL15) that can be pharmacologically controlled using the oral small molecule acetazolamide. In melanoma — where TIL therapies such as Iovance’s Amtagvi have already validated the modality clinically and commercially — OBX-115 is positioning itself as a potentially more controllable and durable next-generation TIL platform.

Why the program matters

Tumor-infiltrating lymphocyte therapy has already demonstrated meaningful activity in checkpoint-refractory melanoma, most notably through Iovance’s Amtagvi, which achieved approximately ~31% ORR with median duration of response not reached in key datasets. However, currently available TIL approaches continue to face major operational and clinical limitations, including manufacturing complexity, variable durability, dependence on exogenous IL-2 administration, and substantial cytokine-related toxicity burden. OBX-115’s core differentiation strategy is built around regulated membrane-bound IL-15 expression, which is intended to improve T-cell persistence and durability while potentially reducing dependence on high-dose systemic cytokines and improving the overall controllability of adoptive cell therapy.

What the program has shown so far

Clinical data remain early, but initial updates demonstrated evidence of T-cell expansion and persistence alongside preliminary antitumor activity in heavily pretreated melanoma patients. Importantly, the safety profile has thus far remained manageable without unexpected cytokine-related toxicities, an encouraging signal given the historical tolerability challenges associated with cellular immunotherapy approaches. The program remains in dose-escalation and early expansion stages, and no mature efficacy dataset has yet been formally released. 

What ASCO 2026 needs to show

The ongoing Phase 1/2 study is designed to evaluate:

• Primary objectives: Safety, dose optimization, and preliminary efficacy 
• Key efficacy measures: ORR, durability, persistence, and tolerability 

To be viewed as technically successful, updated ASCO data will likely need to demonstrate:

• Confirmed ORRs ≥30–35%, at least comparable to the efficacy benchmark established by Iovance’s Amtagvi in checkpoint-refractory melanoma 
• Durable responses extending beyond ~9–12 months 
• Evidence of sustained T-cell persistence 
• Reduced need for intensive IL-2 support 
• Manageable cytokine-related toxicity profile

To be viewed as commercially successful, the program will likely need to demonstrate:

• ORRs approaching or exceeding ~40–50% 
  • (Clearly separating from current salvage regimens and prior TK216 experience) 
• Clear durability advantages over first-generation TIL therapies 
• Operational or tolerability improvements versus Amtagvi 
• Potential reduction in hospitalization burden or cytokine management complexity 
• Scalability advantages sufficient to support broader adoption outside specialized centers

If successful, OBX-115 could become one of the first meaningful next-generation challengers to current TIL therapy approaches in melanoma. Such an outcome would place competitive pressure not only on Iovance’s Amtagvi franchise, but also on the broader field of engineered cell therapies seeking to improve persistence and durability in solid tumors. More broadly, success would validate the concept of pharmacologically regulated cell therapies — an approach that could become increasingly important as the industry seeks to improve the controllability, safety, and scalability of adoptive cell therapy platforms beyond melanoma.

---

Phase 3 Programs

Late-stage oncology development has become increasingly unforgiving, particularly in markets where highly effective standards of care already exist. In many settings, regulatory approval alone is no longer sufficient to ensure meaningful adoption or commercial success. New therapies are now expected to demonstrate clear differentiation in efficacy, durability, tolerability, operational convenience, or long-term treatment value in order to justify their place within increasingly crowded treatment paradigms.

The programs in this section include next-generation targeted inhibitors, targeted delivery platforms, androgen receptor pathway intensification strategies, and novel MAPK-pathway modulation approaches across some of oncology’s largest commercial markets, including lung, bladder, pancreatic, and prostate cancer. Several of these studies are expected to generate data with potentially registrational or practice-changing implications, while others may influence broader competitive dynamics, treatment sequencing strategies, and future expectations surrounding targeted therapy optimization in oncology.

Atebimetinib is one of the more closely watched emerging pancreatic cancer programs heading into ASCO 2026 because it targets one of the field’s most historically difficult pathways: RAS/MAPK signaling. Pancreatic ductal adenocarcinoma is overwhelmingly KRAS-driven, yet decades of efforts to therapeutically inhibit the pathway have produced limited clinical success outside select KRAS mutation subsets. Immuneering’s approach differs from classical MEK inhibition by using a “deep cyclic inhibition” strategy designed to intermittently suppress the MAPK pathway while potentially avoiding some of the chronic toxicities that have historically limited MEK inhibitor combinations. The drug is being evaluated in combination with gemcitabine and nab-paclitaxel (Gem/Nab), one of the standard frontline chemotherapy regimens in metastatic PDAC.

Why the program matters

Metastatic pancreatic ductal adenocarcinoma remains one of oncology’s most difficult therapeutic settings, with frontline regimens typically producing median overall survival of only ~8–11 months and extremely poor long-term survival outcomes. KRAS mutations are present in roughly ~90% of PDAC tumors, yet decades of attempts to therapeutically inhibit the MAPK pathway have yielded limited clinical success outside select KRAS mutation-specific settings. Previous MEK inhibitor strategies were often undermined by insufficient efficacy and poor tolerability in combination regimens. Against this backdrop, Immuneering’s “deep cyclic inhibition” strategy represents an attempt to intermittently suppress MAPK signaling while potentially avoiding the chronic toxicities that historically limited continuous MEK inhibition approaches. The current frontline Gem/Nab benchmark remains relatively modest at approximately ~23% ORR, ~5.5 months median PFS, and ~8.5 months median OS, but meaningful improvement beyond those thresholds has proven exceptionally difficult in PDAC.

What the program has shown so far

Early Phase 1/2 datasets have generated encouraging preliminary signals, with ORRs reported in the ~39–44% range and disease control rates approaching ~90% in early cohorts. Median PFS trends have already appeared to exceed historical Gem/Nab benchmarks, while responses have been observed across multiple KRAS mutation subtypes rather than being restricted to narrowly selected molecular populations. Importantly, the safety profile has remained relatively manageable thus far, particularly with respect to severe MEK-associated toxicities, raising the possibility that intermittent MAPK suppression may improve long-term tolerability relative to historical MEK inhibitor combinations. 

What ASCO 2026 needs to show

The ongoing Phase 1/2 trial is expected to provide updated efficacy and durability analyses at ASCO 2026, with future registrational development likely centered on:

• Primary endpoints: ORR and progression-free survival (PFS) 
• Comparator benchmark: Gem/Nab historical controls and potentially NALIRIFOX in future frontline positioning 

To be viewed as technically successful, updated data will likely need to demonstrate:

• ORRs consistently ≥40%, materially exceeding historical Gem/Nab benchmarks from MPACT trial while approaching efficacy territory associated with more intensive frontline regimens such as NALIRIFOX 
• Median PFS clearly exceeding ~6–7 months 
• Signals that median OS could extend beyond ~11–12 months 
• Durable responses across broader KRAS-mutant populations 
• Continued manageable tolerability without major additive chemotherapy toxicity

To be viewed as commercially successful, the bar is substantially higher:

• Demonstration of survival trends approaching or exceeding current frontline leaders such as NALIRIFOX (~11+ month OS territory) 
  • (Clearly separating from current salvage regimens and prior TK216 experience) 
• Clear efficacy differentiation versus Gem/Nab alone 
• A tolerability profile superior to historical MEK inhibitor combinations 
• Potential applicability across multiple KRAS subtypes rather than niche mutation subsets 
• Ability to integrate into frontline PDAC treatment paradigms without materially increasing chemotherapy burden

If successful, atebimetinib could become one of the first broadly applicable MAPK-pathway strategies to show meaningful clinical benefit in pancreatic cancer, an achievement that would have implications well beyond PDAC itself. Strong data could increase competitive pressure on both KRAS-selective inhibitor developers and other MAPK-pathway programs by supporting the idea that pathway modulation — rather than complete continuous inhibition — may offer a more clinically viable strategy in difficult KRAS-driven tumors. More broadly, success would significantly strengthen Immuneering’s positioning in the increasingly competitive RAS-targeted oncology landscape.

Zelenectide pevedotin is one of the more closely watched urothelial cancer programs heading into ASCO 2026 because it seeks to improve upon a clinically validated mechanism rather than introduce a completely novel target. The drug targets Nectin-4, the same target successfully exploited by enfortumab vedotin (Padcev), but uses Bicycle Therapeutics’ Bicycle Drug Conjugate (BDC) platform instead of a conventional antibody-drug conjugate (ADC). The company’s central hypothesis is that the smaller peptide-based architecture may improve tumor penetration and pharmacokinetics while potentially reducing toxicity associated with MMAE-based therapies.

Nectin-4 is already a commercially validated target in metastatic urothelial carcinoma following the success of Padcev plus pembrolizumab, which rapidly became the dominant frontline standard after EV-302. This creates both a major opportunity and a substantial challenge for Bicycle Therapeutics. On one hand, the biological pathway itself has already been clinically validated. On the other, the efficacy benchmark required to compete meaningfully has become exceptionally high. The central strategic question is therefore whether the Bicycle Drug Conjugate platform can preserve Padcev-like efficacy while improving tolerability, pharmacokinetics, and long-term treatment feasibility through its smaller peptide-based architecture.

What the program has shown so far

Interim Duravelo-1 data generated significant early interest by demonstrating approximately ~45% ORR as monotherapy and roughly ~65% ORR in combination with pembrolizumab in cisplatin-ineligible frontline patients. Importantly, early safety findings suggested potentially lower rates of severe neuropathy and dermatologic toxicity relative to historical Padcev experience. Bicycle Therapeutics has also increasingly positioned Duravelo-2 as a potentially registrational study, reflecting growing confidence that the BDC platform may be capable of supporting regulatory expansion into a commercially important urothelial cancer setting if efficacy and tolerability remain competitive with existing Nectin-4 standards.

What ASCO 2026 needs to show

The ongoing Duravelo-2 Phase 3 study uses:

• Primary endpoint (frontline cohort): Progression-free survival (PFS) 
• Comparator: Platinum chemotherapy ± avelumab maintenance

To be viewed as technically successful, updated data will likely need to demonstrate:

• ORR consistently ≥60–65% in the pembrolizumab combination setting, aligning with the efficacy territory established by Padcev plus pembrolizumab in EV-302 
• Median PFS approaching or exceeding ~12 months
  • (Padcev + pembrolizumab achieved ~12.5 months median PFS in EV-302) 
• Durable responses maintained beyond 9–12 months 
• Lower rates of Grade ≥3 neuropathy and rash than Padcev historically reported (~14–17% neuropathy; ~15% severe skin toxicity) 

To be viewed as commercially successful, the bar is substantially higher:

• Match Padcev efficacy while demonstrating clearly improved tolerability 
• Reduce treatment discontinuation rates below the ~35% range observed historically with Padcev combinations 
• Show enough safety differentiation to justify physician switching in a market already consolidating around Padcev + pembrolizumab 
• Establish a positioning advantage either in:
  • frailer patients, 
  • long-term treatment duration, 
  • or combination flexibility with checkpoint inhibitors

If successful, the implications could extend well beyond urothelial cancer. A strong ASCO 2026 update would not simply validate another Nectin-4 therapy, but could position Bicycle Drug Conjugates as a credible alternative to traditional ADCs in solid tumors. In a market currently dominated by Padcev, demonstrating comparable efficacy with meaningfully improved tolerability could challenge one of the field’s key trade-offs — the assumption that highly effective ADCs must also carry substantial chronic toxicity. Such an outcome could pressure both established and emerging competitors to rethink payload delivery and safety optimization strategies, while simultaneously elevating Bicycle Therapeutics from a single-asset story to a potentially differentiated platform player in targeted oncology.

Zegfrovy (sunvozertinib) is one of the more commercially significant targeted therapy programs expected to report updated data around ASCO 2026 because it addresses one of the most difficult EGFR-driven lung cancer populations: EGFR exon 20 insertion (Ex20ins) NSCLC. Unlike classical EGFR mutations, Ex20ins alterations have historically shown poor sensitivity to earlier EGFR inhibitors, leaving patients with limited targeted options and poor outcomes. Dizal’s strategy is to position sunvozertinib as a next-generation oral EGFR inhibitor specifically optimized for Ex20ins mutations while aiming to improve both efficacy and tolerability relative to existing competitors such as Johnson & Johnson’s amivantamab.

Why the program matters

EGFR Ex20ins NSCLC represents approximately ~2–4% of EGFR-mutant NSCLC and remains one of the most difficult EGFR-driven lung cancer subsets to treat effectively. The competitive benchmark is increasingly defined by amivantamab, which demonstrated approximately ~40% ORR, ~11 months median duration of response, and ~8.3 months median PFS in CHRYSALIS, although at the cost of substantial infusion-related reactions and EGFR-associated toxicities. Mobocertinib previously demonstrated ORRs around ~28% but ultimately struggled with severe diarrhea, dose reductions, and limited long-term commercial competitiveness. Against this backdrop, sunvozertinib is attempting to establish itself as a next-generation oral Ex20ins inhibitor capable of combining durable efficacy, improved tolerability, and the operational advantages of oral administration. 

What the program has shown so far

Earlier WU-KONG studies demonstrated ORRs ranging from approximately ~45–60% depending on line of therapy, with median duration of response approaching ~11–12 months and median PFS ranging roughly ~8–12 months. Activity has also been observed in heavily pretreated patients following platinum chemotherapy. Beyond efficacy itself, the program has already generated important regulatory momentum in China, where sunvozertinib received approval for EGFR Ex20ins NSCLC, while the ongoing Phase 3 study is widely viewed as central to broader global expansion ambitions and potential positioning in earlier treatment settings. Safety has also appeared relatively manageable compared with historical Ex20ins therapies, including lower severe diarrhea burden than mobocertinib and the practical advantages associated with oral administration versus intravenous amivantamab. 

What ASCO 2026 needs to show

The ongoing Phase 3 trial compares sunvozertinib against platinum-based chemotherapy in previously treated EGFR Ex20ins NSCLC, with:

• Primary endpoint: Progression-free survival (PFS) 
• Key secondary endpoints: ORR, OS, duration of response, CNS activity, safety

To be viewed as technically successful, updated data will likely need to demonstrate:

• Median PFS clearly exceeding chemotherapy benchmarks (~4–6 months) 
• ORRs consistently ≥50%, exceeding historical amivantamab efficacy reported in CHRYSALIS and substantially outperforming historical mobocertinib benchmarks 
• Duration of response ≥10–12 months 
• Continued manageable safety profile 
• Evidence of CNS activity comparable or superior to existing Ex20ins therapies 

To be viewed as commercially successful, the program will likely need to demonstrate:

• PFS consistently approaching or exceeding ~10 months 
• Efficacy at least comparable to amivantamab’s ~40% ORR and ~8.3 month PFS benchmark 
• Clear convenience advantage as an oral therapy 
• Lower treatment burden than amivantamab:
  • Reduced infusion-related complications 
  • Lower discontinuation rates 
  • Improved long-term tolerability 
• Potential expansion into earlier-line treatment settings

If successful, sunvozertinib could become one of the first serious oral challengers to Johnson & Johnson’s amivantamab franchise in EGFR Ex20ins NSCLC. Positive Phase 3 outcomes could also accelerate broader regulatory adoption outside China and strengthen the drug’s positioning as one of the first globally competitive oral therapies specifically optimized for EGFR Ex20ins disease. A strong efficacy and tolerability profile could shift physician preference toward oral mutation-selective TKIs, particularly in patients where chronic infusion burden or EGFR-related toxicity are major considerations. More broadly, success would reinforce the growing competitive trend toward highly selective, mutation-specific EGFR inhibitors capable of combining durable efficacy, CNS activity, and improved tolerability in increasingly segmented NSCLC markets.

PROTEUS is one of the more strategically important prostate cancer studies expected around ASCO 2026 because it tests whether intensified androgen receptor inhibition can improve long-term outcomes in patients with high-risk localized prostate cancer undergoing radical prostatectomy. The trial evaluates perioperative Erleada (apalutamide) plus androgen deprivation therapy (ADT) before and after surgery versus ADT alone. While androgen receptor pathway inhibitors are already well established in metastatic prostate cancer, the competitive focus has increasingly shifted toward earlier disease settings where preventing recurrence and metastatic progression could create substantially larger commercial opportunities.

Why the program matters

High-risk localized prostate cancer continues to carry substantial recurrence risk, with up to ~50% of patients eventually recurring following surgery despite multimodal treatment approaches. Current management strategies generally include surgery with or without radiation alongside selective androgen deprivation therapy, but the competitive focus in this setting has increasingly shifted toward metastasis prevention and long-term disease eradication. Historically, true pathologic complete response rates following neoadjuvant hormonal approaches remained in the low single digits, although newer intensified androgen receptor inhibitor combinations have pushed combined pCR/minimal residual disease response rates toward the ~10–20% range. Earlier Phase 2 apalutamide studies also demonstrated strong PSA suppression and improved pathologic response metrics, including 100% biochemical recurrence-free survival at 24 months in the Apa-RP study.

What ASCO 2026 needs to show

PROTEUS evaluates:

• Dual primary endpoints:
  • Pathologic complete response (pCR) 
  • Metastasis-free survival (MFS) 
• Comparator: ADT + placebo before and after radical prostatectomy 

Importantly, no efficacy outcomes from PROTEUS itself have yet been publicly released.

To be viewed as technically successful, initial data will likely need to demonstrate:

• pCR/MRD response rates clearly exceeding the emerging ~10–20% benchmark previously observed in intensified androgen receptor inhibitor studies such as Apa-RP and neoadjuvant abiraterone-based programs 
• Meaningful improvements in residual cancer burden at surgery 
• Early separation in metastasis-free survival trends 
• Durable PSA suppression 
• Manageable perioperative toxicity without compromising surgical feasibility 

To be viewed as commercially successful, the bar is considerably higher:

• Durable MFS benefit substantial enough to justify long-duration androgen receptor inhibition in localized disease
  • Likely requiring hazard ratios approaching ≤0.70 
• Clear reduction in recurrence risk versus surgery/ADT alone 
• Favorable tolerability in a potentially curative patient population 
• Broad adoption potential among both urologists and medical oncologists 
• Competitive differentiation versus:
  • Xtandi (enzalutamide)-based perioperative strategies 
  • Zytiga (abiraterone)-based intensification approaches 
  • Emerging PSMA-guided escalation strategies 

If successful, PROTEUS could materially reshape management of high-risk localized prostate cancer by accelerating the migration of androgen receptor pathway inhibitors into curative-intent settings before metastatic progression occurs. Such an outcome would strengthen Johnson & Johnson’s competitive positioning against Pfizer/Astellas’ Xtandi franchise and abiraterone-based intensification approaches while reinforcing the broader industry trend toward aggressive early intervention in prostate cancer. More broadly, positive data could help redefine recurrence prevention — rather than metastatic disease control alone — as one of the next major commercial battlegrounds in oncology. 

---

Conclusion

ASCO 2026 is expected to feature an increasingly diverse mix of oncology modalities, ranging from next-generation ADCs and radiopharmaceuticals to cell therapies, synthetic lethality strategies, and highly selective targeted inhibitors. Yet across these programs, one common theme continues to emerge: strong clinical outcomes alone are no longer sufficient. Success increasingly depends on context — how a therapy compares against evolving standards of care, how durable and operationally manageable its benefit appears, and whether its differentiation is meaningful enough to alter physician behavior, treatment paradigms, or competitive positioning.

In several cases, the upcoming ASCO data may help clarify broader industry questions surrounding next-generation ADC engineering, biomarker-driven development, recurrence-prevention strategies, cell therapy optimization, and synthetic lethality approaches in solid tumors. More broadly, these readouts may offer important signals regarding where oncology development, competitive dynamics, and future standards of care are heading next.

As oncology development becomes increasingly data-dense and competitively complex, interpreting clinical outcomes in isolation is no longer enough. Effective strategic decision-making increasingly requires the ability to contextualize emerging data against historical development benchmarks, evolving regulatory expectations, competitive landscapes, and shifting standards of care.

At Intelligencia AI, we combine proprietary oncology datasets, AI-driven PTRS modeling, historical benchmarking frameworks, and domain expertise to help organizations evaluate development risk, contextualize clinical performance, and better understand the signals that may shape future scientific and commercial outcomes.

For organizations seeking deeper strategic insight into oncology development and competitive intelligence, we welcome the opportunity to continue the conversation.

---